PMID- 28668864
OWN - NLM
STAT- MEDLINE
DCOM- 20170829
LR  - 20221207
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 7
DP  - 2017 Jul
TI  - Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 
      Cases.
PG  - 3711-3715
AB  - BACKGROUND/AIM: Vascular endothelial growth factor receptor (VEGFR) has been 
      identified as a treatment target for biliary tract cancer (BTC) and axitinib is a 
      selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3. 
      This study was conducted as a preliminary evaluation of the safety and efficacy 
      of axitinib for patients with advanced BTC. PATIENTS AND METHODS: Patients 
      refractory to gemcitabine-based regimens were administered axitinib at the dose 
      of 5 mg twice daily. RESULTS: Five patients (3 male and 2 female) with a median 
      age of 68 years were enrolled. Although 3 patients developed treatment-related 
      grade 3/4 adverse events (AEs), none of these patients required discontinuation 
      of the protocol treatment due to the AEs. Partial response (PR) was achieved in 1 
      patient, with a 67% reduction. The response was classified as stable disease (SD) 
      in 3 patients and as progressive disease (PD) in 1 patient. Overall survival (OS) 
      and progression-free survival (PFS) ranged from 2.0 to 19.9 months and 1.5 to 7.4 
      months, respectively. CONCLUSION: This preliminary study suggested that axitinib 
      is well-tolerated and might exert promising activity in patients with BTC.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Okano, Naohiro
AU  - Okano N
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan naohiro-okano@ks.kyorin-u.ac.jp.
FAU - Kasuga, Akiyoshi
AU  - Kasuga A
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Kawai, Kirio
AU  - Kawai K
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Kobayashi, Takaaki
AU  - Kobayashi T
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Naruge, Daisuke
AU  - Naruge D
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Nagashima, Fumio
AU  - Nagashima F
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
FAU - Furuse, Junji
AU  - Furuse J
AD  - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
      Japan.
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0W860991D6 (Deoxycytidine)
RN  - C9LVQ0YUXG (Axitinib)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Axitinib
MH  - Biliary Tract Neoplasms/diagnostic imaging/*drug therapy/pathology
MH  - Deoxycytidine/adverse effects/analogs & derivatives/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Imidazoles/adverse effects/*therapeutic use
MH  - Indazoles/adverse effects/*therapeutic use
MH  - Lymph Nodes/diagnostic imaging/pathology
MH  - Lymphatic Metastasis/diagnostic imaging/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Tumor Burden/drug effects
MH  - Gemcitabine
OTO - NOTNLM
OT  - Biliary tract cancer
OT  - axitinib
OT  - chemotherapy
OT  - gemcitabine
OT  - vascular endothelial growth factor
EDAT- 2017/07/03 06:00
MHDA- 2017/08/30 06:00
CRDT- 2017/07/03 06:00
PHST- 2017/04/24 00:00 [received]
PHST- 2017/05/22 00:00 [revised]
PHST- 2017/05/23 00:00 [accepted]
PHST- 2017/07/03 06:00 [entrez]
PHST- 2017/07/03 06:00 [pubmed]
PHST- 2017/08/30 06:00 [medline]
AID - 37/7/3711 [pii]
AID - 10.21873/anticanres.11743 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Jul;37(7):3711-3715. doi: 10.21873/anticanres.11743.